Open Label Phase II Study of BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to Gleevec
Status:
Completed
Trial end date:
2005-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the anti-cancer activity and safety of Bay 43-006,
in patients who have Chronic Myelogenous Leukemia that resisted to Gleevec treatment, one of
the standard medication administered for these patients.